What is PBIGF stock price today?

PBIGF (Paradigm Biopharmaceuticals Limited) stock is trading at $0.18 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PBIGF stock going up or down today?

PBIGF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PBIGF stock now?

The decision to buy PBIGF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PBIGF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PBIGF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PBIGF stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PBIGF is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PBIGF's P/E ratio?

P/E ratio data for PBIGF will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PBIGF's market cap?

PBIGF (Paradigm Biopharmaceuticals Limited) has a market capitalization of $0.08 billion, making it a small-cap stock.

What is PBIGF's price to book ratio?

PBIGF trades at a price-to-book (P/B) ratio of 17.56, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PBIGF pay dividends?

PBIGF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PBIGF's dividend yield?

PBIGF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PBIGF stock a good long-term investment?

PBIGF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PBIGF's revenue growth rate?

PBIGF has shown revenue growth of 0.5% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for PBIGF are available on our dashboard with complete income statement analysis.

What are the risks of investing in PBIGF?

Key risks for PBIGF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PBIGF compare to its competitors?

Compare PBIGF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PBIGF's performance and positioning.

What is PBIGF's stock price target for 2026?

Our AI model provides price targets for PBIGF based on fundamental analysis: Bull case $0.23 (+30%), Base case $0.21 (+15%), Bear case $0.16 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PBIGF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PBIGF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PBIGF's next earnings report?

PBIGF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PBIGF - Paradigm Biopharmaceuticals Limited

NYSE * Healthcare * Biotechnology

$0.18

+$0.00 (+0.00%)

About Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

PBIGF Key Statistics

Market Cap

$81.32M

P/B Ratio

17.56

EPS

$-0.07

Revenue Growth

+0.5%

How PBIGF Compares to Peers

PBIGF has the fastest revenue growth among competitors

PBIGF is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PBIGF(This stock)	$81.32M	N/A	1%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Paradigm Biopharmaceuticals Limited Company Information

Headquarters: 500 Collins Street, Melbourne, VIC, Australia, 3000, undefined
Website: www.paradigmbiopharma.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: April 17, 2026 at 2:20 PM EDT

Ready to invest in PBIGF?

Commission-free trading available. Affiliate links.

Upcoming Events for PBIGF

Dashboard

Enter a ticker to analyze